- Sections
- A - Nécessités courantes de la vie
- A61K - Préparations à usage médical, dentaire ou pour la toilette
- A61K 40/42 - Antigènes associés au cancer
Détention brevets de la classe A61K 40/42
Brevets de cette classe: 1540
Historique des publications depuis 10 ans
|
0
|
1
|
8
|
30
|
95
|
130
|
56
|
51
|
811
|
28
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Propriétaires principaux
| Proprétaire |
Total
|
Cette classe
|
|---|---|---|
| The Regents of the University of California | 20315 |
42 |
| The Trustees of the University of Pennsylvania | 4382 |
38 |
| Memorial Sloan-Kettering Cancer Center | 1981 |
27 |
| Kite Pharma, Inc. | 423 |
25 |
| Board of Regents, The University of Texas System | 5959 |
22 |
| Juno Therapeutics, Inc. | 466 |
22 |
| Immunitybio, Inc. | 484 |
21 |
| Autolus Limited | 264 |
18 |
| Dana-Farber Cancer Institute, Inc. | 2621 |
18 |
| Iovance Biotherapeutics, Inc. | 351 |
18 |
| H. Lee Moffitt Cancer Center and Research Institute, Inc. | 991 |
17 |
| The Board of Trustees of the Leland Stanford Junior University | 6552 |
16 |
| The General Hospital Corporation | 4795 |
16 |
| City of Hope | 1009 |
16 |
| The United States of America, as represented by the Secretary, Department of Health and Human Services | 2918 |
16 |
| Fred Hutchinson Cancer Center | 462 |
15 |
| Novartis AG | 10511 |
14 |
| Regeneron Pharmaceuticals, Inc. | 4455 |
14 |
| FATE Therapeutics, Inc. | 213 |
13 |
| Immatics Biotechnologies GmbH | 1150 |
13 |
| Autres propriétaires | 1139 |